Insights
Insights From Our Experts
Articles
The Future of Global Commercialization: Unified, Data-Driven and Patient-Centric
Are you interested in the rapidly evolving pharmaceutical landscape? Do you want to understand the paradigm shift in global commercialization strategies? If so, we have just the resource for you! Download our latest article titled “The…
EVERSANA Experts On-Stage at Frontiers Health 2024
In anticipation of Frontiers Health 2024, EVERSANA is delighted to reveal that several of our key experts will be speaking at this top-tier global health innovation conference! Scheduled for October 17-18th in Berlin, Germany, Frontiers Health…
Canadian Market Access Success Starts With the Right Partner
The Canadian market access and reimbursement environment is in an era of unprecedented change. HTA bodies are transforming their organizations to make review processes more efficient and give Canadians faster access to new drugs (e.g., Target…
EVERSANA’s Predictive Analytics: A Capabilities Compendium
In the fast-changing world of healthcare, machine learning (ML) and real-world evidence (RWE) bring us closer to the goal of precision medicine: delivering the right treatment to the right patient by the right physicians at the…
National Institutes of Health Taps EVERSANA for Research on the Impact of Rare Disease on Patients, Healthcare System
The National Institutes of Health (NIH) has selected EVERSANA, a leading service provider to the life sciences industry, to conduct the next phase of research on the impact of rare diseases on patients and the overall…
IDN Trends, Insights and Strategies Every Manufacturer Should Know
In this latest webinar, hear from three industry experts as the delve into the intricacies of integrated delivery networks (IDNs) and how they are transforming the healthcare landscape. EVERSANA’s Faruk Abdullah and Krista Pinto, and Matthew…
Clinical Data Portability for Regulatory Submissions Across Global Markets
Navigating the regulatory landscape for medical devices is complex, especially in relation to using clinical study data from overseas to support regulatory approval and reimbursement in the U.S., EU and U.K. The key question many companies…
Understanding IDNs and What They Mean to the Pharmaceutical Industry–Q&A with Greg Skalicky
Integrated Delivery Networks have impacted everything from drug launches to sales approaches. Integrated Delivery Networks have changed the healthcare landscape over the past decade. Greg Skalicky, President at EVERSANA, spoke with Pharmaceutical Executive about the ways…
EVERSANA’s Commitment to Health Innovation in Europe: Leading the Charge at Frontiers Health 2024
EVERSANA is leading conversations about next-generation commercialization as the presenting sponsor at the global health innovation event Frontiers Health 2024. As we expand our global reach in Europe and beyond, Frontiers Health represents the perfect event…
Budget Impact Analysis of Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease in Europe
When traditional therapies fail to provide relief from pain caused by lumbar degenerative diseases, surgical approaches such as transforaminal lumbar interbody fusion (TLIF) may be used. TLIF can be performed using traditional open techniques (O-TLIF) or…